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Methotrexate enterotoxicity: Influence of drug dose and
timing in the rat
C.R. Pinkerton* & P.J. Milla
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The early clinical use of folic acid antagonists was
associated with a significant incidence of severe and
often fatal intestinal toxicity. Such complications
rarely occur with modem treatment due to careful
attention to dose tolerance and the use of folinic
acid rescue. Malabsorption of d-xylose has however
been reported in children with acute leukaemia
receiving maintenance therapy (Craft et al., 1977;
Pinkerton et al., 1981) and such patients may
develop severe malabsorptive states (Lewis et al.,
1982; Baird & Dossetor, 1981).
In this study the effects of a range of
methotrexate (MTX) doses on absorptive function
in the rat jejunum have been investigated and the
influence of timing and duration of treatment
considered. It was of particular interest to
determine whether MTX altered absorption in the
absence of villus atrophy and to define the pattern
of functional recovery after MTX induced injury.
Male Wistar rats weighing 250-300g were fasted
for 16h prior to study; water was freely available.
Anaesthesia was induced and maintained with i.p.
pentobarbitone. The steady state perfusion
technique described by Harries & Sladen (1972) was
used. A 15 cm segment of proximal jejunum was
isolated, cannulated at both ends and gently flushed
with warmed saline. The experimental perfusate was
pumped through at a rate of 0.2mlmin-1. After an
initial equilibration period of 50min the effluent
from the distal cannula was collected over 3
consecutive 20min periods. Perfusate contained (per
litre): NaCl 145mmol, KCI 4mmol, NaHCO3
25mmol polyethylene glycol (PEG 4000) 3g with
20yCi [14C] PEG (Radiochemicals, Amersham),
glucose 2mmol. Adjustment of pH to 7 was by
gassing with CO2 and the osmolality of the solution
was 290mosml-1.
Correspondence: C.R. Pinkerton
*Present address: Department of Haematology &
Oncology, The Hospital for Sick Children, Great Ormond
Street, London.
Received 13 June 1983; accepted 23 September 1983.
The initial solution and the effluent were
analysed for sodium by flame photometry and
glucose by colorimetric assay. [14C] PEG
concentrations were measured in 200Il aliquots in
RIA Luma (LKB) using an LKB Wallac
scintillation counter. Water absorption was
estimated using PEG as a non absorbable marker
and the uptake of solutes calculated using standard
formulae.
Three experiments were carried out with
variations in the dose and route of MTX and in the
timing of study after MTX administration:
Three groups were given i.m. doses of 2,10 &
30mgkg 1 and perfused 72h after injection.
Four groups were studied 1,3,7 & 14 days after a
single i.m. dose of 30mgkg-1.
One group received 1 mgkg- by gavage twice
weekly for 4 weeks and were perfused 72h after the
last dose.
In each experiment age and weight matched
control animals that had not received MTX were
studied. Parenterally treated animals received an
intragluteal injection of MTX sodium solution
(Lederle), 25mgml-1 diluted in saline to provide
the appropriate dose in 0.3-0.5ml. For gavage
MTX solution was made up in 1 ml doses.
Specimens ofjejunum were fixed in formalin for
light microscopic study and mucosal morphometry.
In each case crypt depth and villus height were
measured in well orientated areas containing at
least 10 villi.
For statistical analysis of the absorption data
(normally distributed) the unpaired Student's t-test
was used. For jejunal morphometry the Mann
Whitney U test was used.
The effects of 3 doses (2,10 & 30mgkg ')on the
absorption of water, sodium and glucose are
illustrated in Figure 1. At the lowest dose there was
no significant difference between controls and
treated cases. After both 10 & 30mgkg1 sodium
and water absorption were reduced by comparison
with either animals receiving 2mgkg-1 MTX or
untreated controls (P<0.005). Glucose absorption
was less sensitive to MTX and was reduced
significantly only after the highest dose (P<0.02).
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Figure 1 Jejunal absorption of glucose, sodium and water 72h after a single dose of MTX: 2 mgkg- I (n =8),
10mgkg-1 (n =8) and 30mgkg-1 (n =5) compared with untreated controls (n =9). Mean+ s.e. is plotted and
the P values compare MTX treated with controls.
The maximum effects on absorption were seen 3-
7 days after a single dose of 30mgkg-1 (Figure 2).
Twenty-four hours after MTX there was no
significant reduction in water or solute absorption.
Although the mean values of water and sodium
absorption at 7 days indicated some functional
recovery by comparison with 3 days, glucose
absorption was by contrast even further impaired.
Fourteen days after MTX, water and solute
absorption had returned to control values.
After 4 weeks treatment sodium and water
absorption were unimpaired (Figure 3). There was,
however, a significant reduction in the absorption
of glucose compared with untreated animals
(P<0.02). Treated rats appeared to suffer no ill
effects from MTX and were asymptomatic with
weight gains similar to that of the control group.
(Mean 42g/week compared with 35g/week).
The only significant alteration in villus
architecture was seen 72h after the highest dose of
MTX (30mgkg-1) (Table I). In all other cases
there was no significant difference in villus height
or crypt depth compared with untreated controls.
Table I Jejunal mucosal morphometry in control rats
and after treatment with methotrexate. (±s.e.)
Villus height Crypt depth
(pm) (Am)
Untreated controls 370+ 17 195+ 16
MTX treated
24h after 30mgkg-' 357+6 174+5
72h after 2mgkg-1 407+42 193+11
10mgkg-1 345+13 144+30
30mgkg-1 285+40* 124+ 16#
7 days after 30mgkg1 368+35 202+20
*P<0.05
#P<0.005
When given in high doses or for prolonged
periods many cytotoxic agents inhibit intestinal
crypt cell division and cause hypoplastic villus
atrophy (Shaw et al., 1979). MTX in particular has
been shown to cause villus atrophy in the
experimental animal with malabsorption of a wide
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Figure 2 Jejunal absorption of glucose, sodium and water at different times after a single dose of MTX
(30mgkg-'): 1 day (n=6), 3 days (n= 5), 7 days (n=9) and 14 days (n=7) compared with untreated controls
(n= 15). Mean+s.e. is plotted and P values compare treated with untreated controls.
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Figure 3 Jejunal absorption of water, sodium and glucose 3 days after 8 biweekly oral doses of MTX
(I mgkg- I per dose), (n =9), compared with untreated controls, Mean + s.e. is plotted.
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range of drugs and nutrients (Jolly & Fletcher,
1977; Vehno, 1976). In children with acute
leukaemia malabsorption syndromes may not* be
associated with such severe structural dysruption
and the precise cause of the functional
abnormalities is less clear. One aim of the present
study was to determine whether in the experimental
animal functional abnormalities could be induced in
the absence of villus hypoplasia after low doses of
MTX or during the recovery period after a single
high dose. Robinson et al. (1966) have previously
studied the relationship between structure and
function using an in vitro technique but
demonstrated that amino acid absorption was
maintained in some cases despite villus atrophy
rather than the converse.
In the present study it was evident that the low
single dose had no effect on either structure or
function. As was anticipated the highest dose
(30mgkg-1) caused villus atrophy and generalised
malabsorption. At this dose, however, it is difficult
to distinguish any specific effect on enterocyte
function from the non specific effect of reduced
villus surface area caused by severe villus atrophy.
The results of the intermediate dose (10mgkg-1)
were therefore of particular interest. At this dose
glucose absorption was unimpaired but sodium and
water absorption were both reduced. Parallel
abnormalities of sodium and water transport might
have been anticipated as water uptake is dependent
upon the osmotic gradient generated by active
sodium transport.
Malabsorption after a single dose of MTX could
be due either to a direct toxic effect on mature
enterocytes or an indirect effect secondary to
mitotic inhibition in crypt cells. Although the major
action of MTX is on immature dividing cells it may
also damage mature cells due to its effect on RNA
and protein synthesis. This effect, however, is an
early one and impaired enterocyte metabolism has
been demonstrated within several hours of
antifolate administration (Vitale, 1954). In the
present study functional impairment was not seen
24h after the highest dose and it therefore seems
more likely that an indirect mechanism is involved.
A reduction in crypt mitotic activity has been
previously demonstrated in jejunal biopsies after
relatively low doses of MTX; 1-2mgkg-1. (Trier,
1962; Pinkerton et al., 1982) but the cellular
response to such inhibition is variable. This may
range from a harmless delay in cell division to cell
death and appears to depend upon both the
metabolic state of the enterocyte and the stage of
cell division at the time of drug exposure (Farber,
1971). Moreover cells damaged at crypt level may
nonetheless migrate to the villus surface in the
normal manner and although villus architecture is
maintained a significant number of enterocytes may
be functionally deranged. Alternatively, stasis of
villus cell turnover could result with a failure to
replace mature cells at the distal extrusion zone.
The resultant increase in the number of "ageing"
cells might reduce the absorptive efficiency without
any gross structural change. Detailed stathmo-
kinetic studies are required to determine precisely
the effect of MTX on the migration pattern of
crypt cells.
The persisting malabsorption 7 days after MTX
is of particular interest as this may be comparable
to the functional abnormalities found in patients
several days after drug exposure. At this time gross
structural abnormalities are no longer evident
(Table I) and although subtle ultrastructural
changes have been described in jejunal biopsies
taken several days after MTX in such cases jejunal
morphometry was similarly normal. (Gwevava et
al., 1981). A likely explanation for such persisting
dysfunction is the repopulation of villi with
relatively immature cells as a consequence of
reactive crypt hyperplasia. Taminiau (1980) has
demonstrated elevated thymidine kinase
concentrations in rat jejunal mucosa during the
recovery period and crypt hyperplasia has been
described in man (Trier, 1962).
It is of note that glucose absorption was
particularly affected both during the recovery
period and after repeated low dose treatment. It is
possible that repeated inhibition of crypt cell
division over several weeks leads to a similar
imbalance in villus cell turnover. The relative
sparing of structure and function after biweekly low
dose MTX by comparison with low daily or
alternative day doses (Jolly & Fletcher, 1977;
Baskerville & Batter-Hatten, 1977) could have been
due either to the lower cumulative dose or to the
greater time interval between doses. If insufficient
time is allowed between doses the failure of mitotic
recovery leads to crypt hypoplasia and villus
atrophy. It is likely that the greater degree of xylose
malabsorption in children receiving weekly rather
than 3-4 weekly MTX is similarly due to the degree
of mucosal recovery between doses (Pinkerton,
1981).
MTX metabolites and drug recycling may also
contribute to prolonged enterotoxicity. Potentially
toxic hepatic or intestinal metabolites may reach
maximum concentration several days after a single
dose or gradually accumulate with repeated doses.
MTX polyglutamates have been shown to persist in
various tissues for prolonged periods and could
therefore influence enterocyte metabolism.
(Jacobs et al., 1975). Alternatively toxic concen-
trations of MTX may be present in the small
gut as a result of enterohepatic recycling. Such aMETHOTREXATE ENTEROTOXICITY IN THE RAT 101
mechanism has been postulated as the cause of
protracted diarrhoea in a child with leukaemia
(Baird & Dossetor, 1981).
In conclusion it seems likely that MTX induced
malabsorption is not, as is often assumed, simply a
consequence of reduced villus surface area but
involves the interaction of cell toxicity and
alterations in villus population dynamics.
We are grateful to Mr B. Gregory and the staff of the
animal house at the Institute of Child Health and to Ms
F. Byron and Mr A. Phillips of the Dept. of Histo-
pathology, Queen Elizabeth Hospital, Hackney.
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